Contrasting SS Innovations International (NASDAQ:SSII) and AtriCure (NASDAQ:ATRC)

AtriCure (NASDAQ:ATRC) and SS Innovations International (NASDAQ:SSII) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability and earnings.

Earnings and Valuation

This table compares AtriCure and SS Innovations International”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AtriCure	$534.53 million	5.50	-$11.45 million	$0.30	192.60
SS Innovations International	$42.49 million	8.82	-$12.13 million	($0.06)	-31.17

AtriCure has higher revenue and earnings than SS Innovations International. SS Innovations International is trading at a lower price-to-earnings ratio than AtriCure, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

AtriCure has a beta of 1.23, indicating that its share price is 23% more volatile than the S&P 500. Comparatively, SS Innovations International has a beta of -1.52, indicating that its share price is 252% less volatile than the S&P 500.

Institutional and Insider Ownership

99.1% of AtriCure shares are owned by institutional investors. 4.0% of AtriCure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares AtriCure and SS Innovations International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AtriCure	2.52%	4.01%	3.03%
SS Innovations International	-23.73%	-26.77%	-15.01%

Analyst Recommendations

This is a summary of recent recommendations for AtriCure and SS Innovations International, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AtriCure	1	4	6	1	2.58
SS Innovations International	1	0	0	0	1.00

AtriCure currently has a consensus price target of $61.80, indicating a potential upside of 6.96%. SS Innovations International has a consensus price target of $7.00, indicating a potential upside of 274.33%. Given SS Innovations International’s higher possible upside, analysts clearly believe SS Innovations International is more favorable than AtriCure.

Summary

AtriCure beats SS Innovations International on 12 of the 14 factors compared between the two stocks.

About AtriCure

AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercoastal peripheral nerves in the ribcage; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure. In addition, the company sells Lumitip dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.

About SS Innovations International

AVRA Medical Robotics, Inc. develops and manufactures medical surgical devices. The company has a research agreement with the University of Central Florida to develop navigation and control technologies with applications in medical robotics. The company was formerly known as AVRA Surgical Microsystems, Inc. and changed its name to AVRA Medical Robotics, Inc. in November 2015. AVRA Medical Robotics, Inc. was founded in 2015 and is based in Orlando, Florida.